The neonatal Fc receptor (FcRn) is a major histocompatibility complex class I-related molecule that regulates the half-life of IgG and albumin. In addition, FcRn directs the transport of IgG across both mucosal epithelium and placenta and also enhances phagocytosis in neutrophils. This new knowledge gives incentives for the design of IgG and albumin-based diagnostics and therapeutics. To study FcRn in vitro and to select and characterize FcRn binders, large quantities of soluble human FcRn are needed. In this report, we explored the impact of two free cysteine residues (C48 and C251) of the FcRn heavy chain on the overall structure and function of soluble human FcRn and described an improved bacterial production strategy based on removal of these residues, yielding 70 mgAEL )1 of fermentation of refolded soluble human FcRn. The structural and functional integrity was proved by CD, surface plasmon resonance and MALDI-TOF peptide mapping analyses. The strategy may generally be translated to the large-scale production of other major histocompatibility complex class I-related molecules with nonfunctional unpaired cysteine residues. Furthermore, the anti-FcRn response in goats immunized with the FcRn heavy chain alone was analyzed following affinity purification on heavy chain-coupled Sepharose. Importantly, purified antibodies blocked the binding of both ligands to soluble human FcRn and were thus directed to both binding sites. This implies that the FcRn heavy chain, without prior assembly with human b2-microglobulin, contains the relevant epitopes found in soluble human FcRn, and is therefore sufficient to obtain binders to either ligand-binding site. This finding will greatly facilitate the selection and characterization of such binders.
The neonatal Fc receptor (FcRn) is a major histocompatibility complex class I-related molecule that regulates the half-life of IgG and albumin. In addition, FcRn directs the transport of IgG across both mucosal epithelium and placenta and also enhances phagocytosis in neutrophils. This new knowledge gives incentives for the design of IgG and albumin-based diagnostics and therapeutics. To study FcRn in vitro and to select and characterize FcRn binders, large quantities of soluble human FcRn are needed. In this report, we explored the impact of two free cysteine residues (C48 and C251) of the FcRn heavy chain on the overall structure and function of soluble human FcRn and described an improved bacterial production strategy based on removal of these residues, yielding 70 mgAEL )1 of fermentation of refolded soluble human FcRn. The structural and functional integrity was proved by CD, surface plasmon resonance and MALDI-TOF peptide mapping analyses. The strategy may generally be translated to the large-scale production of other major histocompatibility complex class I-related molecules with nonfunctional unpaired cysteine residues. Furthermore, the anti-FcRn response in goats immunized with the FcRn heavy chain alone was analyzed following affinity purification on heavy chain-coupled Sepharose. Importantly, purified antibodies blocked the binding of both ligands to soluble human FcRn and were thus directed to both binding sites. This implies that the FcRn heavy chain, without prior assembly with human b2-microglobulin, contains the relevant epitopes found in soluble human FcRn, and is therefore sufficient to obtain binders to either ligand-binding site. This finding will greatly facilitate the selection and characterization of such binders.
The neonatal Fc receptor (FcRn), which plays a central role in prolonging the half-life of IgG and albumin [1] [2] [3] , is a major histocompatibility complex (MHC) class I-related receptor consisting of a heavy chain (HC) with three ectodomains (a1, a2 and a3), a transmembrane part and a short intracellular signaling tail. Like MHC class I HC, the FcRn counterpart is noncovalently associated with b2-microglobulin (b2m) [4, 5] . Furthermore, FcRn directs the transepithelial transcytosis of maternal IgG over the intestine of neonatal rats [6, 7] and is essential for human IgG transplacental transport in ex vivo experiments [8] [9] [10] , an observation that strongly suggests a role for FcRn in the transfer of maternal IgG from mother to fetus. Moreover, FcRn-mediated transport across cellular barriers has been shown in in vitro intestinal cell lines, in mice and primate studies in vivo [11] [12] [13] , and has been explored as a drug delivery pathway [11, 14] . Expression of FcRn has recently been demonstrated on immune cells such as macrophages, monocytes, dendritic cells and bone marrow-derived phagocytic cells [15, 16] , but a complete understanding of its role in these cells is lacking, except for a report that FcRn participates in phagocytosis in neutrophils [17] . Interaction studies and crystallographic mapping have uncovered the interaction sites on both IgG and FcRn, as reviewed previously [2] . The interaction is highly pH dependent, with binding at acidic pH (pH 6.0-6.5) and no binding ⁄ release from the receptor at physiological pH (pH 7.2-7.4). A key feature is conserved histidine residues localized to the C H 2-C H 3 interface of the IgG Fc, especially H310 and H435 that become protonated at acidic pH to interact with negatively charged residues on the a2 domain of the FcRn HC [2, 4, 18] . Albumin also interacts, in a pH-dependent manner, with an a2 domain site distally from the IgG interaction site [19] , and both ligands may interact with FcRn simultaneously. Importantly, the pH dependence seems to be of fundamental importance in all FcRn-mediated functions.
The molecular understanding of the diverse functions involving FcRn is increasingly being translated into the novel design of antibody-based and albuminbased diagnostics and therapeutics, as demonstrated through the development of IgGs with increased halflife [20] [21] [22] and improved imaging properties [23] [24] [25] , as well as of Fc and albumin fusion products with an increased half-life [26] [27] [28] [29] . Furthermore, IgGs with increased binding to FcRn at physiological pH accelerate the turnover of circulating autoimmune or otherwise pathogenic IgG molecules as they block the IgG site [2, 30] . Thus, development of new specific FcRn binding molecules is attractive, and approaches for the in vitro selection of binders will consistently need large quantities of soluble human FcRn (shFcRn) as well as panning and elution strategies where the pH dependence of the interaction may be carefully controlled.
Four conserved cysteine residues form two disulfide bridges in the MHC class I HC. The hFcRn counterpart has, in addition, two unpaired cysteine residues [4, 5] that complicate heterologous production. We have previously described successful heterologous production of truncated MHC class I molecules [31, 32] and of a shFcRn wild-type (WT) receptor with native binding characteristics [33] . Here, we report on the mutation of two unpaired cysteines to serines (C48S and C251S) and expression of the double mutant HC in Escherichia coli followed by extraction in 8 m urea and subsequent in vitro refolding in the presence of human b2-microglobulin (hb2m). This resulted in a 10-fold increased yield. Furthermore, the structural elements were correctly formed, and stringent reversible pH-dependent binding to human IgG1 (hIgG1) as well as to human serum albumin (HSA) was demonstrated by surface plasmon resonance (SPR) measurements. Subsequently, immunization of goats with either shFcRn or the easily obtained HC gave rise to specific antibodies that inhibited the binding of both ligandshIgG1 and albumin -to shFcRn. The HC could be covalently coupled to Sepharose to form a matrix for the purification or selection of such binders.
Results
Site-directed mutagenesis, expression and purification of a eukaryotic shFcRn C48S ⁄ C251S mutant Six cysteine residues exist within the extracellular part of hFcRn HC [5] , forming one disulfide bond within the a2 domain (C96-C159) and one within the a3 domain (C198-C252). In addition, there are two unpaired cysteine residues, namely C48 and C251, located in the a1 and a3 domains, respectively. The HC-associated hb2m has one disulfide bond (C25-C80). Figure 1A shows a crystallographic illustration of truncated shFcRn (amino acids 1-267 of HC) with the cysteine residues indicated.
To investigate the functional impact of the free cysteines, C48 and C251 were mutated to serines in the truncated HC. Both WT and mutant were expressed as glutathione-S-transferase (GST) fusions in human cells, as previously described [34] . The mutant was secreted at slightly higher levels than the WT. Both were purified and tested for functional pH-dependent binding to hIgG in two different assays. First, the pHdependent hIgG1-binding capacity of shFcRn WT-GST was compared with that of shFcRn C48S ⁄ C251S-GST. The mutant bound as strongly as the WT receptor at pH 6.0, but only weak binding of either was detected at pH 7.4 (Fig. 1B) . A binding experiment using hIgG coupled to Sepharose followed by immunoblotting showed concentration-dependent binding of both shFcRn WT-GST and shFcRn C48S ⁄ C251S-GST at pH 6.0. No binding of either was observed at pH 7.4 or using uncoupled Sepharose at pH 6.0. Mutant shFcRn and WT bound IgG in the same manner (supplementary Fig. S1 ).
Prokaryotic expression of hFcRn C48S ⁄ C251S HCs
To investigate the impact of C48 and C251 on heterologous production, C48S ⁄ C251S HC was produced in E. coli (supplementary Fig. S2 ) and purified as described in the Materials and methods. The yield was 2.5-fold higher (550 mg from a 2 L fermentation) than that obtained for WT. Mutant HC was then added to an in vitro refolding solution together with an independently expressed and purified hb2m [31] . The elution profile from size-exclusion chromatography (SEC) separation of the refolded shFcRn mutant showed three peaks (EL1, EL2 and EL3; Fig. 2A ). EL2 was identified as heterodimeric shFcRn, EL1 as aggregated mutant HC and EL3 as aggregated residual hb2m on nonreducing SDS-PAGE (Fig. 2B) . The total yield of the heterodimeric shFcRn mutant was 140 mg from a 2 L fermentation, increasing the output by approximately 10-fold compared with the WT [33] . Importantly, while only 5% of the WT HCs were refolded upon exposure to hb2m [33] , 26% of the mutant HC was incorporated in complete molecules under the same experimental conditions. Comparing this strategy with classical reduction ⁄ oxidation refolding, the latter produced large amounts of high-molecular-mass aggregates, whereas the disulfide-assisted refolding did not (supplementary Fig. S3 ). Comparison of expression and refolding between the WT and the mutant is summarized in the supplementary (Table S2 ).
Structural and thermal stability analyses of bacterially produced shFcRn
Structural features in addition to thermal stability were determined by CD analyses. Figure 3 shows the CD spectrum for the shFcRn C48S ⁄ C251S with a typical negative peak at 217-218 nm and a positive peak at 195-197 nm. Furthermore, calculation of the secondary structural elements (Table 1 ) was in agreement with previously reported bacterially expressed shFcRn WT and with data obtained by others [4, 5, 35, 36] . In addition, the thermal stability of the shFcRn mutant was demonstrated to generate a midpoint unfolding temperature of 58°C (data not shown), similar to that of WT (58.5°C) [33] .
Mapping of disulfide bonds by MALDI-TOF MS
To investigate the folding of the recombinant receptor variants in greater detail, disulfide mapping was performed by MALDI-TOF MS. Gel-separated protein subunits were digested by trypsin, either after alkylation with iodoacetamide (aliquot 1) or after sequential alkylation with iodoacetamide, reduction and alkylation by iodoacetic acid (aliquot 2). Thus, cysteine residues become alkylated by iodoacetic acid (those engaged in disulfide bonds) or iodoacetamide (free cysteines), respectively, which differ in mass by 1 Da. In the mass spectrum of hb 2 m (aliquot 1), the pronounced signal at m ⁄ z 3250.50 ( (Fig. 5A,B) , indicating that disulfide formation in the a2 domain is not fully complete. The formation of the disulfide bond between C198 and C252, however, appeared to be complete (Fig. 5C,D) . A similar result was obtained for C96, C159 and C198 in the hFcRn WT HC (Fig. 5E-G) .
Surprisingly, residues C251 and C252 were both found to be modified by iodoacetic acid (m ⁄ z 2450.09; Fig. 5H ), although C251 is expected to be unpaired. The pronounced signal at m ⁄ z 2332.06, marked by an asterisk in Fig. 4C (aliquot 1 of WT HC), matches the corresponding tryptic peptide assuming a disulfide bond between the vicinal residues C251 and C252. Indeed, the sequence of that peptide with an intramolecular disulfide bond was proven on a MALDI-TOF ⁄ TOF mass spectrometer (Fig. 6 ). Also, C48 in the a1 domain, which does not participate in disulfide bonding in a correctly folded molecule, was found to be modified by iodoacetic acid (m ⁄ z 2612.13, Fig. 5I ). In general, disulfide bond formation in the WT HC was far more heterogeneous, and deviations from the correct configuration were detected compared with the HC mutant. a The secondary structure elements were estimated as described previously [33] from the CD data obtained from the spectrum presented in Fig. 3 .
Functional properties of bacterially produced shFcRn C48S ⁄ C251S
The ligand-binding properties of refolded shFcRn C48S ⁄ C251S were assessed using SPR. Functional binding to hIgG1 was measured by injecting 1 lm shFcRn mutant over a CM5 chip containing immobilized hIgG1 (Fig. 7A) . The sensorgram demonstrates reversible, pH-dependent binding at pH 6.0 and no binding at pH 7.4. Furthermore, the equilibrium constant (K D ) was calculated from the resonance profiles for near-equilibrium or equilibrium binding levels using BIAevaluation software after injection of 0.012-4 lm shFcRn mutant at pH 6.0. The K D obtained (1.35 ± 0.35 · 10 )6 m) agrees well with that determined by others for the WT [37, 38] . Mutant shFcRn was then immobilized on the chip, serial dilutions of hIgG1 or HSA were injected at pH 6.0 (Fig. 7B ,C) and affinities were derived using the BIAevaluation software. Both ligands showed the expected pH-dependent binding profiles. The binding of HSA fitted well to the 1 : 1 Langmuir binding model to yield a K D of 1.1 ± 0.0 · 10 )6 m, which is in agreement with other reports [19, 39] . Injection of hIgG1 over immobilized shFcRn is known to give rise to complex kinetics, and thus two relevant models were explored -the heterogeneous ligand-binding model and the bivalent analyte model -both supplemented with the BIAevalution Wizard. The heterogeneous ligand-binding model assumes that two parallel and independent interactions (K D1 and K D2 ) take place between the ligand and the receptor, and the derived affinities were determined to be 6.7 ± 0.1 · 10 )9 m (K D1 ) and 219.0 ± 37.7 · 10 )9 m (K D2 ). Thus, the affinity was dramatically increased to the nm range when using this model, as has been reported previously [5, 11, 33] . The bivalent analyte model assumes that both sides of the symmetric ] . Additive binding was obtained when both ligands (hIgG1 and HSA) were injected over the immobilized shFcRn mutant at pH 6.0 (Fig. 7D) . Affinity measurements were also performed using a preparation of the shFcRn mutant where the N-terminal hexa-histidine tag (HAT-tag) was removed, and the resulting data exclude the possibility that the tag contributes to ligand binding (data not shown). Importantly, hFcRn binds human, rabbit and guinea-pig IgG, but it does not bind to mouse, rat, bovine or sheep IgG, with the exception of weak binding to murine IgG2b [38, 40] . Samples of the 0.25 lm shFcRn mutant were injected over high levels ( 700-1000 RU) of immobilized murine IgG1 and IgG2b, with identical specificity at pH 6.0. The SPR sensorgrams showed no binding to murine IgG1 and weak binding to murine IgG2b (supplementary Fig. S4) . Thus, the mutant, like the WT, discriminates between murine IgGs, and behaves like the WT also in all other aspects analyzed.
We then measured the binding of a carcinoembryonic antigen scFv-Fc antibody variant to the mutant shFcRn. This scFv-Fc, denoted H310A ⁄ H435Q, has shown promising results in preclinical tumor-imaging evaluations [24] . SPR analyses were performed using an immobilized receptor and injection of 0.5 lm WT scFv-Fc at pH 6.0. The sensorgrams clearly demonstrate that the WT scFv-Fc interacts with shFcRn, whereas the H310A ⁄ H435Q variant does not (Fig. 7E) . This explains the dramatically decreased half-life of H310A ⁄ H435Q compared with the WT in the anti-carcinoembryonic antigen tumor-imaging study performed in mice [24, 25] .
Antigenic properties of bacterially produced FcRn C48S ⁄ C251S HC
To investigate the antigenic properties of the bacterially produced preparations, female goats were immunized with shFcRn C48S ⁄ C251S or HC. Serum collected post immunization was tested for the presence of anti-FcRn Ig in an ELISA on wells directly coated with mutant shFcRn or hb2m (Fig. 8A,B) . While serum obtained from goat immunized with mutant shFcRn reacted towards both shFcRn and hb2m, serum obtained from goat immunized with HC showed no reactivity towards hb2m, but did bind shFcRn.
Antibodies from goat immunized with HC were purified on HC-coupled Sepharose. Elution was performed sequentially using four different buffer conditions (EL1-EL4), as described in the Materials and methods. The eluted fractions migrated as bands corresponding to 150 kDa on nonreducing SDS-PAGE and reacted in a concentration-dependent manner with mutant shFcRn in an ELISA (supplementary Fig. S5A,B) . Thus, HC Sepharose affinity matrix can be utilized to purify antiFcRn-specific Ig and, consequently, elution conditions can be chosen as desired.
Next, sera from goats immunized with the shFcRn mutant were purified in a large-scale operation on HCcoupled Sepharose. The eluted purified fractions (Fig. 8C ) bound shFcRn in ELISA (Fig. 8D) , while only a trace of hb2m reactivity was detected (Fig. 8E) . Thus, the HC-coupled affinity matrix could exclude all anti-hb2m reactivity present in the sera.
Importantly, the purified antibody preparation from the HC-immunized goat inhibited pH-dependent binding of both ligands, IgG and HSA (Fig. 9A,B) . Similar results were obtained for anti-FcRn Ig obtained from goat immunized with the shFcRn mutant (data not shown). Goat IgG from pre-immune serum purified on a protein-G column did not block the binding sites. In conclusion, these data imply that the HC, without prior assembly with hb2m, is sufficient for immunization to obtain binders to both ligand-binding sites on shFcRn, and that such binders may be isolated on an HC-coupled affinity matrix.
Discussion
We have recently reported a bacterial expression strategy that generates functional nonglycosylated shFcRn WT with native binding characteristics [33] . This strategy relies on solubilization of extracted HCs in 8 m urea buffer under nonreducing conditions, a process that disrupts the tertiary structure but keeps the preformed disulfide bond configuration intact before in vitro refolding on hb2m. Although the strategy was successful, only 5% of purified HCs assembled with hb2m.
Bacteria lack the complex folding machinery of eukaryotes, therefore, both native and scrambled disulfide bonds are formed. Furthermore, disulfide bonds may be generated in inclusion bodies and during extraction and ⁄ or purification. The situation becomes even more complex when the protein consists of more than one subunit, such as heterodimeric FcRn.
Sequence and crystallographic analyses have shown the presence of disulfide bonds and, in addition, two unpaired cysteine residues (C48 and C251) localized to the ectodomains of the hFcRn HC [4, 5] . Theoretically, 64 possible disulfide bonds can be made by the six cysteines involved. The C48S ⁄ C251S double mutant with four cysteine residues may fold into 10 possible configurations, namely one completely reduced, six partially oxidized (with one disulfide bond), and three completely oxidized (with two disulfide bonds). Initially, analyses of the double mutant expressed in a eukaryotic system using human embryonic kidney (HEK) 293E cells showed that the mutations had no effect on the production yield and pH-dependent binding to IgG. Subsequently, when the double mutant was produced in the bacterial system, we found a great effect on the refolding output. First, the amount of higher aggregates during all purification steps was dramatically decreased compared with the WT and, second, the refolded yield was 135 mg per 2 L fermentation, corresponding to an increase of 10-fold compared with the WT. Even more favorably, 26% of the mutant HC assembled with hb2m compared with only 5% for the WT HC. Mutant shFcRn and WT showed similar secondary structures, according to CD measurements, as described previously for WT [4, 5, 35, 36] . Therefore, to investigate the folding of both hb 2 m and the hFcRn HCs, the configuration of disulfide bonds was qualitatively investigated using a combination of MALDI-TOF MS and chemical alkylation of cysteine residues. The expected disulfide bonds were demonstrated in hb 2 m and the mutant. However, in the WT molecule the disulfides appeared to be more heterogeneous, with some deviations from the correct configuration. As the signal intensities for disulfide-bonded peptides tend to be low, rare disulfide-bonded peptides with incorrect oxidation may be overlooked. Tryptic peptides that carry alkylated cysteine residues are easier to detect, but then information regarding which cysteines actually pair with each other is lost. By combining the methods, a disulfide bond between vicinal cysteine residues 251 and 252 were observed in the native molecule. The influence of such a bond on the structure of the protein is difficult to predict, but disulfide bonds between adjacent cysteine residues have previously been reported to induce the formation of a tight turn (type VIII turn) of the protein backbone [41] .
Replacement of the two unpaired cysteine residues with serines did not affect the functional activity of mutant shFcRn, as shown by characteristic pH-dependent binding to both ligands. In addition, no binding to murine IgG1, and only weak binding to murine IgG2b at pH 6.0, was observed, and this stringency binding is characteristic for the human receptor [38, 40] . Taken together, neither C48 nor C251 are directly or indirectly involved in the stringent pH-dependent ligand binding of the soluble receptor. However, they may well be functionally important in vivo. Others have indicated that the membrane-anchored form of hFcRn can exist both as a noncovalent and a covalent dimer, in contrast to the secreted recombinant form of hFcRn that does not dimerize [42] . The covalent dimers are proposed to be created by interchain disulfide bonds by the exposed and available C48 and C251. Importantly, the strategy described may prove successful for the production of other nonclassical MHC class I-related molecules as well as FcRn from different species. All HCs contain at least two intact disulfide bonds and various numbers of unpaired cysteine residues. For instance, C48 and C251 are partially conserved in published FcRn HC sequences, and several other MHC class I-related molecules contain putative unpaired cysteine residues (supplementary Tables S3  and S4) .
A number of reports exists that describe the design and selection of mutant IgG molecules with altered binding to FcRn [2, [20] [21] [22] 30, 43, 44] . These involve changes of amino acids in the Fc region, either directly at the FcRn-binding interface or surrounding residues. Furthermore, any protein might be given an increased half-life by fusion to a normal or modified Fc region, as well as to albumin or to an albuminbinding molecule. One would also expect that new molecules will be selected that mimic the ability of albumin or the Fc region to bind FcRn. Several binding scaffolds with various binding specificities currently in preclinical and clinical trials may be used for such selection [45] [46] [47] [48] .
Successful selection depends on whether or not quantities of pure target are available. In this report we describe a simple and cost-effective way to generate large quantities of functional mutant shFcRn, as well as monomeric mutant HC. The antigenic properties of mutant shFcRn and the corresponding HC were investigated by immunization of goats. Goat was chosen as host because shFcRn, as well as other Fc gamma receptors, do not bind detectably to goat ⁄ sheep IgGs [40, 49] . HC-coupled Sepharose affinity matrix was generated and shown to capture anti-hFcRn specific Ig from goat sera following immunization with mutant HC and shFcRn. Commonly used techniques for purification of antibodies take advantage of such affinity molecules as protein G, A and L that are directed against conserved structures, but do not distinguish between antibodies with different specificities or discriminate against irrelevant antibodies present in animal sera. Affinity purification with the mutant HC column allows purification of anti-hFcRn specific Ig. Importantly, anti-hb2m specific Ig are not copurified. This is important, as hb2m is found on all cells as part of MHC class I, in addition in other related molecules (listed in the supplementary Tables S3 and S4). We found that antibodies from immune sera bound shFcRn in ELISA when the shFcRn protein was coated in wells. One may argue that the shFcRn preparation denatures during the coating procedure, and that the serum contains antibodies that bind denatured shFcRn. Even if such specificities are present, there is also a fraction that binds shFcRn in the native conformation. This was demonstrated in the experiment where shFcRn was pre-incubated with antibodies induced by the HC and purified on HC-Sepharose. After incubation, the shFcRn-goat antibody complexes no longer bound either of the two ligands, HSA and hIgG1. The finding that affinity-purified antibody could block pH-dependent binding of IgG and albumin to shFcRn, implies that antibodies were generated that recognized either of the ligand-binding sites located in the a2 domain. Thus, the antigenic properties of the HC in this region are sufficiently similar to those found in the heterodimeric soluble receptor for HC to be utilized for immunization, purification and selection of antibodies or other binders. The HC preparation used for immunization was the same that was utilized for refolding, where 26% of the molecules were captured by hb2m and later found to have native disulfide bridges. Taken together, this suggests to us that the HC preparation described here may well be utilized for immunization of other mammals. The data support the idea that shFcRn as well as the mutant HC, without prior assembly with b2m, is sufficient to obtain binders to either binding site on FcRn. This finding will greatly facilitate the selection and characterization of new FcRn targeting binders.
Materials and methods

Production and purification of eukaryotic shFcRn molecules
The cDNAs encoding truncated WT HC (amino acids 1-268) and hb 2 m (amino acids 1-99) were cloned as described previously [34] . Primers (supplementary Table S1 ) introduced the C48S and C251S mutations into the HC, resulting in HC C48S ⁄ C251S cDNA. The cDNA segments were subcloned in-frame of GST into pcDNA3-GST-oriP [denoted pcDNA3(oriP)-hFcRn(WT)-b2m and pcDNA3(oriP)-hFcRn(C48S ⁄ C251S)-b2m], as described previously [34] . The constructs were transiently transfected into adherent HEK 293E cells and the supernatants were harvested [34] . Expressed shFcRn-GST fusion molecules were purified using the GSTrapÔ FF 5 mL column (GE Healthcare, Oslo, Norway).
Cloning and prokaryotic expression of hFcRn HC variants
The cDNA encoding mutant HC, without the leader sequence (amino acids 1-268), was PCR amplified as described for WT HC [33] , and subsequently cloned into pET28+ (Novagen, Darmstadt, Germany) containing a HAT-tag, denoted pET28-HAT-hFcRn (HC C48S ⁄ C251S). Plasmids were transformed into E. coli BL21 (DE3), as described by Strategene. Recombinant hb2m cDNA was introduced and expressed in the pET28 system, as previously described [31, 32] . The HAT-tag was cleaved using the Factor Xa kit from Novagen.
Expression and extraction of mutant HCs from inclusion bodies and all purification steps were performed as described previously [31, 33] . SDS-PAGE analysis and refolding of purified HCs variants, in 8 m urea buffer with a fourfold molar excess of hb2m, were performed as described for the WT [33] . For experiments using reducing agent, 11-lL samples of hFcRn HCs, WT and C48S ⁄ C251S (3 mgAEmL 
Binding of shFcRn WT and mutant shFcRn to IgG
Binding of the shFcRn-GST variants to ligand was performed by ELISA, as previously described [19] . Human IgG coupled to Sepharose TM 6 Fast Flow or nonconjugated Sepharose (GE Healthcare) was washed in NaCl ⁄ P i , blocked in 2% skimmed milk (SM; Acumedia) then washed in NaCl ⁄ P i ⁄ 0.05% Tween 20, pH 6.0 or pH 8.0. Samples of 1-5 lg of shFcRn were diluted in 1 mL of 2% SM in NaCl ⁄ P i ⁄ 0.05% Tween 20 (pH 6.0 or pH 7.4), incubated by rotation for 1 h, followed by three washing steps in 1 mL of NaCl ⁄ P i ⁄ 0.05% Tween 20 at pH 6.0 or pH 7.4 on rotation for 5 min followed by centrifugation at 12 000 g for 5 min between each step. After the last washing step, 100 ll of NaCl ⁄ P i ⁄ 0.05% Tween 20 at pH 7.4 was added and incubated for 1 hr on rotation followed by centrifugation at 12 000 g. The pooled fractions were separated by SDS-PAGE (12% gel) (Bio-Rad Laboratories, Hercules, CA, USA) and then blotted onto a poly(vinylidene fluoride) membrane (Millipore Corporation, Bedford, MA, USA) in Tris ⁄ glycine buffer at 100 V for 1.5 h. The membranes were blocked in NaCl ⁄ P i containing 4% SM for 1 h at room temperature (20-22°C), washed in NaCl ⁄ P i ⁄ 0.05% Tween 20 and incubated with goat anti-hFcRn (G3290) serum followed by mouse anti-goat horseradish peroxidase (Sigma-Aldrich) at room temperature (20-22°C) for 1 h. Then, the membranes were washed thoroughly with NaCl ⁄ P i ⁄ 0.05% Tween 20, incubated in a mixture of SuperSignal solution (Pierce Chemical Co., Rockford, IL) for 1 min, after which the reactions were visualized on a Kodak XAR film.
CD
CD spectra were recorded, and secondary-structure elements and thermal stability were estimated, as previously described [33] .
Production of goat antisera
Female goats were immunized subcutaneously with 50 lg of mutant shFcRn or mutant HC in 500 lL of NaCl ⁄ P i (pH 7.3) and 750 lL of Freund's complete adjuvant (Difco, Detroit, MI, USA). On day 11 a booster dose (50 lg) was given with Freund's incomplete adjuvant (Difco), and repeated after 24, 66 and 105 days, and the collected and pooled sera were denoted G3290 (mutant shFcRn) and G2248 (mutant HC). The experiments were conducted in accordance with the laws and regulations controlling procedures in live animals in Norway (Norwegian Institute of Public Health).
Binding studies using SPR
Biacore 3000 (GE Healthcare) was used and CM5 sensor chips were coupled with hIgG1 ( 1200 RU), mouse IgG1 ( 1000 RU), mouse IgG2b ( 700 RU) or shFcRn C48 ⁄ C251S (100-1000 RU) using amine coupling chemistry, all as described by the manufacturer. The coupling was performed by injecting 10-12 lgAEmL )1 of each protein into 10 mm sodium acetate, pH 5.0 (GE Healthcare). All experiments were performed in phosphate buffer (67 mm phosphate buffer, 0.15 m NaCl) at pH 6.0 or pH 7.4, or in HBS ⁄ EP buffer (0.01 m HEPES, 0.15 m NaCl, 3 mm EDTA, 0.005% Surfactant P20) at pH 7.4 (GE Healthcare). Dilutions (4-0.012 lm) of mutant shFcRn were injected over immobilized hIgG1 or HSA, or dilutions of HSA (10-0.7 lm), hIgG1 (1-0.003 lm), scFv-Fc WT (0.5 lm) and scFv-Fc H310A ⁄ H435Q (0.5 lm) were injected over immobilized mutant shFcRn. Samples of 0.25 lm shFcRn mutant was injected over mouse IgG1 and mouse IgG2b. The scFv-Fc WT and H310A ⁄ H435Q variants were produced as previously described [24] . All experiments were performed at a flow rate of 30-50 lLAEmin )1 at 25°C.
The flow cells were 'stripped' after each dissociation phase over immobilized shFcRn mutant in phosphate buffer at pH 7.4. In competitive analyses, 30 lm HSA and 0.5 lm hIgG1 were injected alone or together at pH 6.0 over immobilized shFcRn mutant. In all experiments, data were zero adjusted and the reference cell value subtracted. Binding analyses were performed using the Langmuir binding model (1 : 1 binding interaction), the heterogeneous ligand-binding model or the bivalent analyte binding model supplemented with the BIAevaluation wizard.
ELISA analyses of anti-FcRn reactivity
Wells of ELISA plates were coated with 100 lL of mutant shFcRn or hb2m (Abcam) at 2 lgAEmL )1 , and blocked with 4% SM (Acumedia) for 1 h. Collected sera taken preimmunization and postimmunization (G3290 and G2248) were diluted, added to the wells and incubated for 1 h at 20-22°C. Bound anti-FcRn Ig was detected using horseradish peroxidase-conjugated protein G (Calbiochem, Darmstadt, Germany). The ELISAs were developed by adding 100 lL of substrate 2,2¢-azinobis(3-ethylbenzo-6-thiazolinesulfonic acid) ⁄ H 2 O 2 (Sigma-Aldrich).
Preparation of a HC column
Small-scale and large-scale coupling were performed using urea-dissolved mutant HC at 0.001-0.64 mgAEmL Tris ⁄ HCl (pH 9.0) and subjected to 12% nonreducing SDS-PAGE (Bio-Rad Laboratories) analyses. Fractions were pooled, the buffer was changed and the samples were concentrated using Amocon Plus 20 (YM-50) centrifugal filter devices (Millipore) and stored at 4°C. Total goat IgG was purified from sera samples using a commercial protein G-coupled affinity matrix (GE Healthcare).
Inhibition of IgG and HSA binding by anti-FcRn
Inhibition of IgG and HSA binding was performed using pH-dependent ELISA assays, as described previously [19] , except that 100 ll of anti-5-iodo-4-hydroxy-3-nitro-phenacetyl (NIP) hIgG1 (0.5 lgAEmL )1 ) was added to each well and incubated for 1 h at 20-22°C. Then the wells were washed four times with NaCl ⁄ P i ⁄ 0.05% Tween 20, pH 6.0. shFcRn-GST (2 mgAEmL )1 ) was pre-incubated with purified anti-hFcRn HC goat Ig (0.03-4.8 lm) or pre-immune goat IgG (4.8 lm), in NaCl ⁄ P i ⁄ 0.05% Tween 20, pH 6.0, for 30 min at room temperature (20-22°C), and then 100 ll was added to each well. Fig. S1 . pH-dependent binding of shFcRn-GST variants to hIgG-coupled Sepharose. Fig. S2 . Boiled and reduced samples of hFcRn C48S ⁄ C251S HC analyzed by SDS-PAGE (12% gel). Fig. S3 . Nonreducing SDS-PAGE analyses after classical reduction ⁄ oxidation in vitro refolding versus oxidative disulfide-assisted in vitro refolding. Fig. S4 . Binding of mIgG1 and mIgG2b to the shFcRn mutant. Fig. S5 . Nonreducing SDS-PAGE separation and ELISA of antibodies eluted sequentially from HC-coupled Sepharose 4 Fast Flow matrix. Table S1 . Primer sequences. Table S2 . Summary of purification and refolding steps for human HC variants. Table S3 . Numbers of cysteine residues of FcRn HCs across species a . Table S4 . Numbers of cysteine residues of nonclassical MHC class I HC a . This material is available as part of the online article from http://www.blackwell-synergy.com
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